Eosinophils are bone marrow (BM)-derived myeloid cells that differentiate under the control of the transcription factors GATA-1, PU.1, c/EBP, and the common β chain (βc)-signaling cytokines interleukin 5 (IL-5), IL-3 and granulocyte macrophage-colony stimulating factor (GM-CSF)^[@R1]^. IL-5 is the most potent and specific cytokine for the eosinophil lineage and is responsible for cellular expansion^[@R2]^, release from the bone marrow (BM) into the peripheral blood (PB)^[@R3]^, and survival^[@R4]^ following a variety of triggers, typically T~H~2 stimuli. At baseline, eosinophils mainly reside in the gastrointestinal tract, fat pads, spleen, lymph nodes and thymus^[@R5],\ [@R6]^ where they function to maintain homeostasis^[@R6]-[@R8]^. Yet, in settings of allergic inflammation such as those found in asthma, eosinophils expand in the BM and infiltrate the lung where their accumulation is a characteristic disease hallmark^[@R5],\ [@R7]^. While the extrinsic pathways (e.g. IL-5) that regulate eosinophil expansion are relatively well characterized, the presence of intrinsic, self-limiting, molecular checkpoints regulating IL-5-induced eosinophilia is largely unknown and remains to be defined.

A major checkpoint in curtailing cytotoxic T cells and natural killer (NK) cells is inhibitory signaling driven by major histocompatibility complex (MHC) restricted self-recognition, mediated by receptors that are capable of recognizing self via MHC-I-binding. The T cell receptor (TCR) enables positive and negative selection, which is critical for adaptive immunity while avoiding autoreactivity^[@R9]^. NK cell inhibitory receptors (KIR) govern cytotoxicity towards virally infected or transformed cells^[@R10]^.

An additional receptor system that mediates self-recognition by binding to classical and non-classical MHC-I molecules has drawn considerable less attention. This receptor system is comprised of the paired immunoglobulin-like receptors (PIR)-A and PIR-B^[@R11]^. PIRs are predominantly expressed by myeloid cells endowing them with the potential to discriminate self from non-self^[@R12]^. Comprehensive structural and biochemical analyses have shown that the amino acid sequences of the PIR-A and PIR-B ectodomains are over 92% identical and bind the same MHC-I ligands^[@R12],[@R13]^. The deduced structure of PIR-B is a type I transmembrane glycoprotein with six extracellular immunoglobulin-like domains, a hydrophobic transmembrane segment, and an intracellular polypeptide with four immunoreceptor tyrosine-based inhibitory motifs (ITIM) or ITIM-like sequences^[@R12]^. In contrast, PIR-A lacks the extended intracellular motif and requires assistance of adaptor molecules, such as the FcRγ chain for efficient expression and function^[@R12],\ [@R14]^. Subsequent binding of MHC-I molecules by PIRs leads to the recruitment of cytosolic phosphatases by PIR-B, which ultimately results in inhibition of yet undefined signaling cascades triggered by PIR-A^[@R14],\ [@R15]^. Of specific interest, PIR-B is capable of suppressing cellular responses elicited by the βc-signaling cytokines, IL-3 and GM-CSF^[@R16],\ [@R17]^ as well as by Flt-3L^[@R18]^, thus suggesting a role for PIR-B in myeloid cell hematopoiesis. The recent demonstration that eosinophils express PIRs^[@R19]^ together with the suggested hematopoietic functions of PIR-B raised the hypothesis that PIR-B may regulate IL-5-induced responses in eosinophils.

In this study, we demonstrate a critical role for PIR-B and PIR-A in eosinophil development. PIR-B suppressed PIR-A-induced eosinophil apoptosis, thereby counterbalancing survival and growth signals selectively driven by IL-5. PIR expression was regulated by IL-5 and increased during distinct eosinophil maturation stages. Eosinophils maintained a dominant expression of PIR-B over PIR-A under homeostatic conditions. Thus, despite abundant MHC-I ligand availability, which may trigger PIR-A-induced apoptosis, eosinophil development was intact due to inhibitory signals driven by PIR-B. Furthermore, we demonstrate that PIR-A bound the adaptor protein Grb2 and that apoptotic eosinophils displayed increased Erk activation and Bim expression. These data open a new paradigm in our understanding of the intrinsic molecular pathways regulating IL-5-induced eosinophilia and highlight self-recognition via PIRs as a key molecular checkpoint in eosinophil expansion.

Results {#S1}
=======

PIR-B is required for eosinophil differentiation *in vitro* {#S2}
-----------------------------------------------------------

To begin to assess the function of PIR-B in eosinophils, we used the recently described BM-derived eosinophil cell culture system^[@R20]^. Cultures obtained from the low-density (LD) fraction of wild-type BM displayed by day fourteen \>95% eosinophils of uniform morphological appearance, including stereotypical bilobed nuclei ([Fig. 1a](#F1){ref-type="fig"}, day 14). In contrast, starting from day 10, cultures of *Pirb*^−/−^ LDBM cells showed the appearance of myeloid morphology (represented by the black arrows) and by day 14, the entire *Pirb*^−/−^ culture was comprised of large often-multinucleated cells lacking eosinophil morphology (represented by the dotted arrows, [Fig 1a](#F1){ref-type="fig"}). Total cell counts that were obtained from the *Pirb*^−/−^ LDBM cultures were lower than those obtained from wild-type cultures ([Fig. 1b](#F1){ref-type="fig"}). At day 14, cells retrieved from wild-type but not *Pirb*^−/−^ cultures expressed CCR3 ([Fig. 1c](#F1){ref-type="fig"}) and major basic protein (MBP) ([Fig. 1d](#F1){ref-type="fig"}) both of which are classical eosinophil markers. Moreover, *Pirb*^−/−^ cells exhibited distinct physical parameters (i.e. granularity and size, [Fig. 1e](#F1){ref-type="fig"}). Furthermore, *Pirb*^−/−^ cells expressed increased expression of myeloid-associated adhesion molecules and activation markers including CD11b, CD18, α~5~ integrin, CD103, CD62L, and CD69 ([Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}). LDBM culture-derived *Pirb*^−/−^ cells displayed markedly decreased mRNA encoding the eosinophil-associated transcription factors GATA-1 and GATA-2 ([Fig. 1f,g](#F1){ref-type="fig"}), though c/EBP, PU.1 and Fog-1 expression were comparable to wild-type controls (data not shown). By the end of the cell cultures, total eosinophil counts in *Pirb*^−/−^ LDBM cultures were reduced by 97.3 ± 0.06% as compared to wild-type cultures ([Fig. 1h](#F1){ref-type="fig"}). Decreased eosinophil generation was not due to alterations in the numbers of eosinophil progenitors (EoPs) (defined as Sca1^−^CD34^+^Lin^−^c-kit^int^IL-5Rα^+^, [Fig. 1i,j](#F1){ref-type="fig"})^[@R21]^ or alteration in IL-5Rα surface expression in EoPs ([Fig. 1k](#F1){ref-type="fig"}). The inability to generate mature eosinophils *in vitro* was an intrinsic defect of *Pirb*^−/−^ cells since growing *Pirb*^−/−^ cells in supernatants obtained from wild-type LDBM-derived eosinophil cultures did not render the *Pirb*^−/−^ cells into eosinophils. Moreover, the generation of eosinophils was not impaired when cultured in supernatants harvested from *Pirb*^−/−^ cultures (data not shown). Importantly, the requirement of PIR-B in eosinophil development was PIR-B and eosinophil specific since we were able to generate mature eosinophils from LDBM cells of other ITIM-bearing receptor deficient mice (e.g. CMRF35-like molecule (CLM)-1^[@R22]^) and *Pirb*^−/−^ BM yielded normal numbers of macrophages, dendritic cells (DCs), neutrophils and mast cells in the respective cytokine-driven cultures (data not shown and^[@R16],\ [@R23],\ [@R24]^). Collectively, these data indicate that PIR-B regulates an intrinsic pathway, which is specifically required for eosinophilopoiesis.

PIR-B regulates eosinophil apoptosis {#S3}
------------------------------------

Impaired eosinophil development in *Pirb*^−/−^ LDBM cell cultures could be either due to a decreased proliferative ability or to increased apoptosis. Assessment of cellular proliferation in response to a combination SCF plus Flt-3L during the first two days of LDBM cell culture revealed no difference between the proliferative activity of wild-type and *Pirb*^−/−^ EoPs ([Supplementary Fig. 2a](#SD3){ref-type="supplementary-material"}). Due to the loss of the distinct EoP cell surface markers (i.e. C-Kit, IL-5Rα) after 1-2 days in culture, we subsequently assessed cell proliferation in the general LDBM cultures and observed no proliferative difference between wild-type and *Pirb*^−/−^ cells ([Supplementary Fig. 2b](#SD3){ref-type="supplementary-material"}).

Morphological assessment of *Pirb*^−/−^ LDBM cell cultures revealed the presence of apoptotic eosinophils as identified by nuclear fragmentation and cell blebbing ([Fig. 2a](#F2){ref-type="fig"}). Moreover, apoptotic eosinophils and/or apoptotic bodies in *Pirb*^−/−^ cultures were observed to be engulfed by the abundant mononuclear myeloid cells in these cultures ([Fig. 2b](#F2){ref-type="fig"}). In accordance with these findings, assessment of early and late apoptosis using Annexin-V staining combined with propidium iodide (PI), revealed that *Pirb*^−/−^ LDBM cell cultures contained a prominent fraction of Annexin-V^+^PI^−^ cells ([Fig. 2c,d](#F2){ref-type="fig"}). Co-staining for Siglec-F, an early eosinophil development surface marker^[@R25]^ and Annexin-V demonstrated that starting at day 10 of the culture, nearly 20% of the *Pirb*^−/−^ LDBM cells were Siglec-F^+^Annexin-V^+^ comprising approximately half of all *Pirb*^−/−^Siglec-F^+^ cells ([Fig. 2e](#F2){ref-type="fig"}); in contrast, wild-type eosinophils showed good viability and exhibited only 3-5% Siglec-F^+^Annexin-V^+^ cells. Increased percentage of Siglec-F^+^Annexin-V^+^ cells in *Pirb*^−/−^ cultures ([Fig. 2f](#F2){ref-type="fig"}) was reflected by increased total dead eosinophils ([Fig. 2g](#F2){ref-type="fig"}). Eventually, the numbers of total dead eosinophils declined due to the overall decrease in total cell counts, which was observed in the *Pirb*^−/−^ LDBM culture ([Fig. 1b](#F1){ref-type="fig"}). Analysis of the percentage and total Siglec-F^+^Annexin-V^−^ cells demonstrated markedly increased percentage and total viable eosinophils in the wild-type cell cultures in comparison with the *Pirb*^−/−^ cell cultures ([Fig. 2h,i](#F2){ref-type="fig"}).

Consistent with their apoptotic appearance, Siglec-F^+^Annexin-V^+^ cells in *Pirb*^−/−^ LDBM cultures expressed increased expression of active caspase 3 ([Fig. 2j](#F2){ref-type="fig"}). Moreover, *Pirb*^−/−^ LDBM cell cultures displayed increased mRNA expression of the pro-apoptotic molecule Bcl-interacting molecule (Bim)^[@R26]^ in comparison to wild-type cells ([Fig. 2k](#F2){ref-type="fig"}). No differences were observed in the expression of additional pro- or anti-apoptotic molecules ([Supplementary Fig. 3a-c](#SD4){ref-type="supplementary-material"}). Indeed, *Pirb*^−/−^ Siglec-F^+^Annexin-V^+^ cells displayed substantially increased amounts of Bim compared with Siglec-F^+^Annexin-V^−^ wild-type or *Pirb*^−/−^ cells ([Fig. 2l](#F2){ref-type="fig"}). Intracellular staining assessing GATA-1 abundance demonstrated that *Pirb*^−/−^ Siglec-F^+^Annexin-V^+^ cells displayed less GATA-1 protein compared with Siglec-F^+^Annexin-V^−^ wild-type or *Pirb*^−/−^ cells ([Fig. 2m](#F2){ref-type="fig"}). GATA-1 and Bim protein expression was similar between wild-type and mutant Siglec-F^+^Annexin-V^−^ and Siglec-F^−^Annexin V^−^ cells ([Fig. 2l,m](#F2){ref-type="fig"}). Thus, *Pirb*^−/−^ cells do not mature into eosinophils *in vitro* likely due to Bim-mediated apoptosis.

PIR-B is required for IL-5-induced colony formation {#S4}
---------------------------------------------------

To further assess the specificity of PIR-B to IL-5-induced eosinophil differentiation wild-type and *Pirb*^−/−^ LDBM cells were subjected to colony forming unit (CFU) assays using IL-5, GM-CSF or IL-3. *Pirb*^−/−^ cells displayed a specific decrease in IL-5- but not IL-3-and/or GM-CSF-induced CFUs ([Fig. 3](#F3){ref-type="fig"}). Assessment of the relative cell counts per colony demonstrated that the amount of cells per colony was lower in IL-5-induced (but not IL-3- or GM-CSF-induced) *Pirb*^−/−^ CFUs ([Fig. 3](#F3){ref-type="fig"}). Furthermore, *Pirb*^−/−^ CFUs displayed a 2-fold increase in Siglec-F^+^Annexin-V^+^ cells specifically in the IL-5-driven colonies ([Fig. 3c](#F3){ref-type="fig"}). Thus, in response to IL-5 (specifically), *Pirb*^−/−^ BM produced fewer colonies, which were smaller and displayed increased apoptosis in comparison with wild-type cells.

PIR-B regulates eosinophil apoptosis in vivo {#S5}
--------------------------------------------

The requirement for PIR-B in IL-5-induced eosinophil development *in vitro* led us to assess eosinophil numbers in the BM of naïve *Pirb*^−/−^ mice. Flow cytometric analysis of BM eosinophils revealed two distinct eosinophil populations in the BM; namely a Siglec-F^+^CCR3^int^ population and a Siglec-F^+^CCR3^hi^ population (likely representing immature and mature eosinophils, respectively)^[@R25]^, both of which displayed eosinophil physical parameters ([Fig. 4a](#F4){ref-type="fig"}), morphology and eosinophil granule proteins (e.g. MBP, [Supplementary Fig. 4](#SD5){ref-type="supplementary-material"}). Both eosinophil populations retrieved from naïve *Pirb*^−/−^ mice displayed more Annexin-V^+^ staining, as compared to wild-type controls ([Fig. 4b,c](#F4){ref-type="fig"}). Analysis of other BM-resident myeloid cell populations such as monocytes (gated as Ly6G^−^Ly6B.2^+^, R1, [Fig. 4d](#F4){ref-type="fig"}) or neutrophils (gated as Ly6G^+^Ly6B.2^int^, R2, [Fig. 4d](#F4){ref-type="fig"}) revealed that increased baseline apoptosis in *Pirb*^−/−^ mice was specific to eosinophils ([Fig. 4d](#F4){ref-type="fig"}). Assessment of PB of naïve wild-type and mutant mice revealed that the *Pirb* deficiency resulted in 30% fewer blood eosinophils in the steady-state ([Fig. 4e,f](#F4){ref-type="fig"}). Eosinophil viability was similar between wild-type and *Pirb*^−/−^ PB eosinophils (data not shown), suggesting that reduction is due to a compartmentalized apoptotic fate in the BM.

Previous studies utilizing *Il5*^−/−^ mice as well as anti-IL-5 neutralization *in vivo* revealed that under homeostatic conditions, BM eosinophils are only partially regulated by an IL-5-dependent pathway^[@R27],\ [@R28]^. Rather, IL-5 is critical in eosinophil expansion under various disease settings^[@R29]^. To define whether PIR-B regulates *in vivo* steady-state eosinophilia in an IL-5-dependent fashion, IL-5 was neutralized in naïve wild-type and *Pirb*^−/−^ mice using the TRFK5 antibody^[@R30]^. IL-5 neutralization caused an evident (but not complete) decrease in BM and PB eosinophils of wild-type but not *Pirb*^−/−^ mice ([Fig. 4g--i](#F4){ref-type="fig"}). Moreover, anti-IL-5-treatment caused a specific reduction in the expression of PIR-B but not PIR-A in mature BM eosinophils (i.e. Siglec-F^+^CCR3^hi^) but not PB eosinophils ([Fig. 4j](#F4){ref-type="fig"}). Collectively, these data demonstrate that PIR-B regulates the IL-5-dependent but not IL-5-independent baseline frequencies of eosinophils.

Consistently, increased apoptosis of *Pirb*^−/−^ BM eosinophils persisted even when IL-5 availability was artificially elevated by exogeneous delivery of recombinant IL-5. Thus, while this regimen was capable to decrease the apoptotic fate of some *Pirb*^−/−^ Siglec-F^+^CCR3^int^ and Siglec-F^+^CCR3^hi^ cells ([Fig. 4k,l](#F4){ref-type="fig"}), the frequencies of apoptotic eosinophils were still higher in *Pirb*^−/−^ mice in comparison to wild-type controls ([Fig. 4k,l](#F4){ref-type="fig"}). The frequency of eosinophils in the blood of IL-5-treated wild-type animals increased 1.76 ± 0.17-fold whereas; IL-5-treated *Pirb*^−/−^ mice displayed only a 1.2 ± 0.025-fold increase ([Fig. 4m](#F4){ref-type="fig"}). Moreover, IL-5-treatment increased the expression of PIR-B in BM but not PB eosinophils ([Fig. 4n--p](#F4){ref-type="fig"}). These results establish an intricate relationship between IL-5 and PIR expression.

Self-recognition regulates eosinophil expanison {#S6}
-----------------------------------------------

The β~2~ microglobulin (β~2~M) subunit of MHC-I molecules serves as a ligand for PIR-B^[@R11]^. Thus, we hypothesized that loss of β~2~M will result in similar eosinophil apoptosis as observed in *Pirb*^−/−^ cell cultures and mice. Surprisingly however, CFU counts obtained from *B~2~m*^−/−^ LDBM cells demonstrated increased numbers of colonies in response to IL-5 ([Fig. 5a](#F5){ref-type="fig"}). Furthermore, assessment of relative cell counts per colony revealed more cells in the *B~2~m*^−/−^ CFUs ([Fig. 5b](#F5){ref-type="fig"}) and less Siglec-F^+^Annexin-V^+^ cells compared with wild-type cells ([Fig. 5c](#F5){ref-type="fig"}). Consistently, both Siglec-F^+^CCR3^int^ and Siglec-F^+^CCR3^hi^ BM eosinophils obtained from naïve *B~2~m*^−/−^ mice were less apoptotic than naïve wild-type BM eosinophils ([Fig. 5d,e](#F5){ref-type="fig"}). The finding that loss of MHC-I recognition resulted in decreased eosinophil apoptosis suggested the involvement of an additional receptor, which can bind MHC-1 and is suppressed by PIR-B, such as PIR-A^[@R13]^.

Absence of PIR-B enables pro-apoptotic signals by PIR-A {#S7}
-------------------------------------------------------

To address the hypothesis that PIR-A delivers pro-apoptotic signaling in eosinophils, we first analyzed the expression of PIRs throughout the LDBM culture system. Both PIRs were progressively upregulated on the cultured cells ([Fig. 6a](#F6){ref-type="fig"}). Expression of PIR-A preceded that of PIR-B by 2 days, with PIR-A increasing at day 5 ([Fig. 6a](#F6){ref-type="fig"}). The induction of PIR-A (but not of PIR-B) expression thus correlated with the induction of the pro-apoptotic factor Bim ([Fig. 6b](#F6){ref-type="fig"} and [Supplementary Fig. 5](#SD6){ref-type="supplementary-material"}). To assess whether PIR-A is responsible for the apoptotic phenotype that was observed in *Pirb*^−/−^ LDBM cultures, PIR-A was neutralized in the *Pirb*^−/−^ LDBM eosinophil cell cultures using the anti-PIR-A/B antibody 6C1. This antibody was specifically chosen since it recognizes ectodomain 1 and 2 of PIR molecules, which are the major MHC-I recognizing ectodomains in PIRs^[@R31]^.

Neutralization of PIR-A markedly attenuated the apoptotic phenotype, which was observed in *Pirb*^−/−^ eosinophils ([Fig. 6c,d](#F6){ref-type="fig"}) and the numbers of mature eosinophils were noticeably increased ([Fig. 6e,f](#F6){ref-type="fig"}). *Pirb*^−/−^ cultures, which received isotype control antibodies, displayed a similar number of apoptotic cells and total eosinophils as untreated *Pirb*^−/−^ cultures ([Fig. 6e](#F6){ref-type="fig"}). Morphologically, PIR-A neutralization partially restored the typical eosinophil granular appearance in *Pirb*^−/−^ cell cultures ([Fig. 6f](#F6){ref-type="fig"}). Collectively, these data demonstrate that unless counteracted by PIR-B, PIR-A induces eosinophil apoptosis, an activity that is revealed in the absence of PIR-B.

To gain mechanistic insight into the functional activities driven by PIR-A, we have utilized a mini-phosphoproteomic approach where PIR-A was immunoprecipitated from the surface of sorted viable *Pirb*^−/−^ LDBM cells and incubated with a membrane that was pre-coated with antibodies against various signaling molecules ([Supplementary Fig. 6a,b](#SD7){ref-type="supplementary-material"}). After incubation, the membrane was blotted with anti-phospho-tyrosine, thus detecting interactions between PIR-A and functional downstream signaling intermediates. Given the abundant availability of MHC-I ligands to PIR-A, we hypothesized that the kinases and/or adaptor molecules interacting with PIR-A will be active as well. We found that PIR-A was strongly associated with the adaptor Grb2 ([Fig. 6g](#F6){ref-type="fig"}). Given the association between Grb2 and Erk activation^[@R32]^, we hypothesized that apoptotic *Pirb*^−/−^ eosinophils will display increased Erk activation in comparison with viable cells. Assessment of phopho-Erk-1/2, in Siglec-F^+^Annexin-V^−^ and Siglec-F^+^Annexin-V^+^ cells revealed an evident increase in Erk-1/2 phosphorylation in Siglec-F^+^Annexin-V^+^ in comparison with Siglec-F^+^Annexin-V^−^ cells ([Fig. 6h,i](#F6){ref-type="fig"}). Notably, this effect was specific to ERK1/2 activation since activation of Jnk and p38 were not changed between viable and dead eosinophils ([Supplementary Fig. 6](#SD7){ref-type="supplementary-material"}).

Distinct expression for PIRs during eosinophil maturation {#S8}
---------------------------------------------------------

Given the pro-apoptotic role of PIR-A, we sought to understand why do peripheral eosinophils survive in the presence of abundant MHC-I expression. To this end, we analyzed the relative expression of PIR-A and PIR-B in various eosinophil populations in the BM (i.e. EoPs, Sigec-F^+^CCR3^int^, Sigec-F^+^CCR3^hi^ cells), PB and tissue (i.e. peritoneal cavity). EoPs expressed very low and equivalent amounts of PIR-A and PIR-B (1.11 ± 0.02 and 1.14 ± 0.04, fold-increase over isotype control, *P* = 0.26, respectively). The expression of PIR-A and PIR-B gradually increased as eosinophils developed ([Fig. 6j](#F6){ref-type="fig"}) and eosinophils displayed higher amounts of PIR-B in comparison with PIR-A. Therefore, although PIRs compete and bind the same ligands^[@R13]^, pro-apoptotic signaling by PIR-A in eosinophils is constitutively balanced by inhibitory signals mediated by PIR-B, due to its relatively higher expression.

PIR-B is required for allergic airway inflammation {#S9}
--------------------------------------------------

Regulation of eosinophil development by PIRs suggested a role for PIRs in allergic eosinophilic airway inflammation. Therefore, wild-type and *Pirb*^−/−^ mice were sensitized and exposed to extracts of the aeroallergens *Aspergillus fumigatus* (Asp) or house dust mite (HDM). These models were specifically chosen since mucosal aeroallergen-challenged *Pirb*^−/−^ mice displayed similar induction of IgE compared to wild-type mice ([Fig. 7a](#F7){ref-type="fig"}). In contrast, systemic OVA and Alum sensitization of *Pirb*^−/−^ mice results in increased total IgE production, which is likely due to the dysregulation of DC functions^[@R16]^ ([Supplementary Fig. 7a](#SD8){ref-type="supplementary-material"}). Mucosal aeroallergen-challenge had no effect on the apoptotic frequency of wild-type BM eosinophils ([Fig. 7b,c](#F7){ref-type="fig"}). However, it was not sufficient to fully rescue BM *Pirb*^−/−^ eosinophils from apoptosis ([Fig. 7b,c](#F7){ref-type="fig"}). Subsequently, aeroallergen-challenged *Pirb*^−/−^ mice displayed a significant reduction in aeroallergen-induced PB eosinophilia ([Fig. 7d](#F7){ref-type="fig"}) and had less eosinophilic BAL infiltrates ([Fig. 6e,f](#F6){ref-type="fig"}). This phenotype was not due to increased local eosinophil cell death in the lungs as *Pirb*^−/−^ mice displayed similar frequencies of Annexin-V^+^Siglec-F^+^CCR3^hi^ cells as wild-type mice ([Fig. 7g](#F7){ref-type="fig"}). Decreased lung eosinophilia in aeroallergen-challenged *Pirb*^−/−^ mice was also associated with a minor but statistically significant decrease in CD4^+^ T cell accumulation (*P* \< 0.01) and decreased expression of T~H~2 cytokines and chemokines, including IL-4, IL-13 and CCL17 ([Supplementary Fig. 7b--e](#SD8){ref-type="supplementary-material"}). Decreased eosinophilia and T~H~2-associated allergic airway disease were not an allergen-specific phenomenon since also HDM-challenged *Pirb*^−/−^ mice exhibited less lung eosinophil infiltration as well ([Supplementary Fig. 7f,g](#SD8){ref-type="supplementary-material"}).

Since PIR-B is also expressed in myeloid cells other than eosinophils, impaired lung eosinophilia in aeroallergen-challenged *Pirb*^−/−^ mice could result from deficiency in these cells. To specifically probe for the involvement of CD11c^+^ myeloid cells in the impaired response of the *Pirb*^−/−^ mice to the aeroallergen-challenge, we generated animals that harbor a specific PIR-B deficiency in their CD11c^+^ cell compartment (including lung DCs and alveolar macrophages), using a mixed BM chimera approach^[@R33],[@R34]^. Diphtheria toxin (DTx) treatment of mixed BM chimeras generated with CD11c-DTR BM and *Pirb*^−/−^ BM result in animals that retain a *Pirb*-deficient DC compartment, while other hematopoietic cell populations retain their mixed wild-type:*Pirb*^−/−^ make up ([Supplementary Fig. 7h--j](#SD8){ref-type="supplementary-material"}). Restricted absence of PIR-B from CD11c^+^ myeloid cells did not affect the ability of the mice to respond to Asp as CD11c-DTR *Pirb*^−/−^ chimeric mice displayed similar expression of IL-4 and CCL17, as CD11c-DTR/wild-type control chimeras ([Supplementary Fig. 7k,l](#SD8){ref-type="supplementary-material"}). Taken together, these data demonstrate that decreased eosinophil accumulation and T~H~2-associated inflammation is not due to the expression of PIR-B in CD11c^+^ cells, rather it is likely an eosinophil-dependent phenomenon.

Discussion {#S10}
==========

The ability to discriminate "self" from "non-self" via binding of MHC-I molecules is a major immunological concept leading to tolerance of cytotoxic T cells and NK cells^[@R35]^. However, myeloid cells are also capable of self-recognition through PIR-A and PIR-B, which elicit activating and inhibitory signaling, respectively^[@R11]^. In this study, we dissected the function of the MHC-I binding receptors PIR-A and PIR-B in eosinophil maturation and subsequent allergic airway responses and demonstrated key roles for PIRs in IL-5-induced eosinophil expansion.

IL-5 has an exclusive requirement for the rapid expansion of eosinophils especially in disease settings such as asthma^[@R27]^. Our findings demonstrate that IL-5-regulated eosinophilia is governed by a constant "tugging war" with PIR-A. T~H~2 settings (such as those observed in asthma) substantially increase the ability of IL-5 to induce eosinophilia by strengthening the "positive" signals for eosinophil development. Eosinophils likely escape their apoptotic fate, which is regulated by PIR-A, exit the BM and enter the PB, consequently migrating into the inflamed tissue. PIR-B, which is hierarchically dominant to PIR-A, serves as a "permissive" checkpoint for IL-5-induced eosinophil development by suppressing the activities of PIR-A. Thus, a constant crosstalk between PIR-A (acting as a pro-apoptotic "vector") and IL-5 and PIR-B (acting as anti-apoptotic "vectors") exists in eosinophils. Collectively, our model demonstrates that upon self-recognition, PIR-B is a negative regulator of PIR-A-induced apoptosis, which counter balances IL-5-mediated expansion signals ([Figure S8](#SD9){ref-type="supplementary-material"}).

Various candidate "self"-recognizing molecules are widely (and sometime exclusively) expressed by myeloid cells including eosinophils. These include PIRs^[@R19],\ [@R36]^, CD200 molecules; Siglec-family receptors and CD47, which interacts with signal regulatory protein-α (SIRP-α, also known as CD172)^[@R37]^. Despite this, the requirement for self-recognition in eosinophil activities is unknown. Our data demonstrates that inhibitory signaling by PIR-B is dominant over PIR-A induced eosinophil apoptosis and raises the question on how can this occur if they both bind similar ligands? One evident explanation for the relative dominance of PIR-B over PIR-A is the finding that eosinophils express higher amounts of PIR-B than PIR-A and therefore MHC-I binding will lead to more inhibitory signals than pro-apoptotic signaling, consequently maintaining high eosinophil survival rate. Interestingly, IL-5 neutralization caused a specific decrease in PIR-B expression and shifted the balance towards dominant expression of PIR-A relative to PIR-B. Conversely, IL-5 administration resulted in a compartmentalized increase in PIR-B expression (and to lesser extent PIR-A) in BM eosinophils. These data suggest that PIRs constitute an additional "fine-tuning" mechanism regulating IL-5-driven eosinophilia. Hence, increased IL-5 abundance will result in decreased apoptosis due to increased pro-survival signals that are directly mediated by IL-5 receptor; and decreased apoptosis due to increased PIR-B expression, suppressing PIR-A-induced apoptosis. Similarly, the absence of IL-5 renders eosinophils apoptotic due to lack of survival signals directly mediated by IL-5 and increased apoptotic signaling by PIR-A -due to decreased PIR-B expression and hence lack of inhibition.

We have recently established that *Pirb*^−/−^ mice display increased tissue eosinophilia in the gastrointestinal tract^[@R19]^ and adipose tissue (data not shown). Thus, despite increased BM eosinophil apoptosis in *Pirb*^−/−^, steady-state eosinophil numbers in the gastrointestinal compartment are elevated. This is likely due to the fact that the regulation of eosinophil expansion by PIRs is restricted to the BM compartment. Once eosinophils "escape" the developmental regulation by PIRs and enter the blood, PIR-B is capable of suppressing eosinophil CCR3 signaling and subsequent eosinophil migration^[@R19]^. Therefore, tissues that display a constant eotaxin-gradient such as the gastrointestinal tract and adipose tissue will display eosinophilia in the absence of PIR-B^[@R6],\ [@R38]^. Indeed, intratracheal administration of IL-13 that generates a strong chemotactic gradient for eosinophil recruitment (but not IL-5-dependent generation of eosinophils in the BM) results in increased lung eosinophil accumulation in *Pirb*^−/−^ mice^[@R19]^. In contrast to IL-13-administration, under typical T~H~2 settings, rapid IL-5-induced eosinophil generation in the BM occurs, and PIR-B is required for eosinophil generation and subsequent lung infiltration. While we cannot entirely exclude the involvement of additional mechanisms governed by PIR-B in T~H~2 settings, the finding that the expression of PIR-B in the CD11c^+^ myeloid cell compartment is dispensable for decreased T~H~2-associated disease in *Pirb*^−/−^ mice and the finding that mucosal sensitization was similar between wild-type and *Pirb*^−/−^ mice strongly suggests that decreased CD4^+^ T cell accumulation and expression of T~H~2-associated cytokines and chemokines is eosinophil dependent. In support of this notion, numerous studies demonstrate a key contribution for eosinophils in the development of allergic asthma partially by their ability to regulate local lung T~H~2 immunity^[@R5],\ [@R39]-[@R41]^.

Mechanistically, our data suggest that PIR-B does not regulate IL-5-induced eosinophil expansion by direct interactions with IL-5 receptor signaling components (similar to the way PIR-B regulates GM-CSF and/or IL-3-induced responses^[@R16],\ [@R17]^). This finding is of particular interest since it is different than the current reported interactions of other ITIM-bearing receptors with IL-5 receptor. For example, IL-5 primes the pro-apoptotic effects of Siglec-8^[@R42]^, and increased IL-5 expression potentiates the suppression of IL-5-induced survival by CD300a^[@R43]^. Collectively suggesting direct interactions of these inhibitory receptors with IL-5 receptor. In addition, we demonstrate that PIR-A associated with the adaptor molecule Grb2, an upstream regulator of the Mek-Erk pathway^[@R32]^. This interaction is likely mediated via the FcRγ chain, which is required for PIR-A's surface expression^[@R12]^, has been shown to interact with Grb2^[@R44]^, and can mediate pro-apoptotic signaling^[@R45]^. Interestingly, and similar to our findings suggesting a role for Erk in PIR-A-mediated eosinophil apoptosis, Erk activation has been identified as critical in delivering pro-apoptotic signals via Siglec-8 in IL-5-activated eosinophils^[@R42]^.

In summary, we provide evidence that self-recognition of MHC-I molecules by PIRs has a critical role in eosinophil development and consequent expansion in settings of allergic airway disease. These data open a new paradigm in understanding the molecular pathways regulating eosinophilia and have broad implications for eosinophilic diseases.

Methods {#S11}
=======

Mice {#S12}
----

Male and female, 6- to 8-week-old *Pirb*^−/−^ mice (backcrossed \>F9 to C57BL/6)^[@R16]^. CC10-*Il13*^Tg^ and MHC-class I-deficient (*B2m*^−/−^) mice were recently described elsewhere^[@R46],\ [@R47]^. C57BL/6 wild-type (WT) mice were obtained from Harlan Laboratories. 6-week-old CD11c-diphtheria toxin receptor (DTR) transgenic mice (B6.FVB-Tg(Itgax-DTR/GFP)57Lan/J) were used for generation of BM chimeras^[@R33]^. In all experiments age-, weight and gender-matched mice were housed under specific pathogen-free conditions according to Tel-Aviv University and/or Weizmann Institute Animal Care Committee approved protocols.

Eosinophil bone-marrow culture {#S13}
------------------------------

Eosinophils were grown from the BM of WT and *Pirb*^−/−^ mice with modifications based on a prior report^[@R20]^. Briefly, BM cells were harvested and loaded on a histopaque gradient (Sigma). Low-density BM cells were collected and cultured in the presence of SCF and Flt3L for 4 days. Thereafter, the medium was replaced with IL-5 for the rest of the culture (up to day 14). All cytokines were purchased from Peprotech.

Cell proliferation {#S14}
------------------

Cell proliferation was assessed using the Click-iT EdU kit (Invitrogen) according to the manufacturers' instructions.

Allergen sensitization and challenge {#S15}
------------------------------------

Allergic eosinophilic airway inflammation was induced by challenging mice intranasally with either *A. fumigatus (*Asp) or house dust mite (HDM)(Bayer Pharmaceuticals), three times a week for 2-3 weeks as previously described^[@R19]^. In brief, mice were lightly anesthetized with isoflurane inhalation, and 10 μg of total Asp protein extract in 50 μl saline was applied to the nasal cavity by using a micropipette with the mouse held in the supine position. After instillation, mice were held upright until alert. Mice were euthanized 24--48 h after the last challenge and bronchoalveolar lavage was performed and assessed for differential cell counts and mediator content as described^[@R19]^. The concentration of LPS in the Asp extracts was less than 2 pg/ml as detected by the Limulus assay.

IL-5 administration and neutralization {#S16}
--------------------------------------

WT and *Pirb*^−/−^ mice were treated with recombinant mouse IL-5 (5 μg/mouse) or anti-IL-5 (TRFK5 antibody, 50 μg/mouse) for 5 consecutive days. Thereafter, the mice were sacrificed and BM and blood were obtained for flow cytometric analyses.

Real-time quantitative (q) PCR {#S17}
------------------------------

RNA samples from the whole lung were subjected to reverse transcription analysis using SuperScript II reverse transcriptase (Invitrogen) according to manufacturer's instructions. qPCR analysis was performed using the CFX96 system (Bio-Rad laboratories) in conjunction with the ready-to-use fast-start SYBR Green I Master reaction kit (Roche Diagnostic Systems). Results were normalized to *Hprt* cDNA as previously described ^[@R24]^. The primers that were used in this study were as follows: *Il4,* Fwd- TCAACCCCCAGCTAGTTGTC, Rev- TGTTCTTCGTTGCTGTGAGG; *Mbp,* Fwd-CAAAGCTCAGTCAGTTTGCC, Rev- ATCGAAAGCGTTTGCATCGG; *Gata1,* Fwd-TCAAGCTCCATCAGGTGAACC, Rev- TCCCTTTGCCAGATGCCTT; *Pu.1,* Fwd-CCCGGATGTGCTTCCCTTAT, Rev- TCCAAGCCATCAGCTTCTCC, *Fog1,* Fwd-AGCTGTGACCCTGATGGTGG, Rev- GGCGTCATCCTTCCTGTAGATCT; *Gata2,* Fwd- AGACGACAACCACCACCTTA, Rev- TCCTTCTTCATGGTCAGTGG; *c/Ebpa,* Fwd- GTTAGCCATGTGGTAGGAGACA, Rev- CCCAGCCGTTAGTGAAGAGT; *Bcl2,* Fwd-GTCCCGCCTCTTCACCTTTCAG, Rev- GATTCTGGTGTTTCCCCGTTGG; *Bax,* Fwd- GCGTGGTTGCCCTCTTCTACTTTG, Rev-AGTCCAGTGTCCAGCCCATGATG; *Bim*, Fwd-CGACAGTCTCAGGAGGAACC, Rev-CCTTCTCCATACCAGACGGA; *Bid,* Fwd-TGGAAAGACCTTGGCCTGAAGACA, Rev-AAGGTACATGGTGTGGATGCAGGA; *Bad,* Fwd- GAGTATGTTCCAGATCCCAG, Rev-GTCCTCGAAAAGGGCTAAGC; *Pirb,* Fwd- GGTGACAGGACACTACTGGAACCC, Rev-CCACGAGAGCTTCTGTGGTCCT; *Il5ra,* Fwd- ACACTTTTCCAGCATTCGGCT, Rev- TGCCTTTGCTCTTGGTCAGG; *Hprt*, Fwd- GTAATGATCAGTCAACGGGGGAC, Rev-CCAGCAAGCTTGCAACCTTAACCA.

Flow cytometry {#S18}
--------------

Flow cytometric analysis of LDBM cells and enzymatically digested lung or bronchoalveolar lavage cells was conducted using the following antibodies (all purchased from eBioscience unless stated otherwise): anti-PIR-A/B (10-1-PIR), anti-CD62L (MEL-14), anti-β7-FITC (FIB27, Biolegend), anti-α~5~-FITC (HMA5-1), anti-CD48 (HM-48-1), anti-CD18 (M18/2), anti-CD69 (H1.2F3), anti-CD103 (2E7), anti-F4/80 (BM8), anti-CD86 (GL1), anti-MHC-II (NIMR-4), anti-PIR-A/B (6C1,BD Bioscience) anti-CD45 (30-F11), anti-CD11c (N418), anti-CD11b (M1/70), anti-B220 (RA3-6B2), anti-Gr-1 (RB6-8C5), anti-CD3 (145-2C11), anti-CD3 (17A2), anti-CD4 (GK1.5), anti-CD8 (SK1), anti-Siglec-F (E50-2440, BD Bioscience) and anti-CCR3 (83101, R&D Systems). Events were acquired by a Gallios flow cytometer system (Beckman Coulter) or FACScalibur (BD Bioscience) and data were analyzed using the Kaluza (Beckman Coulter) or FlowJo (TreeStar) software on at least 10,000-50,000 events. Surface molecule expression was calculated by defining the delta mean fluorescent intensity between the specific antibody stain and the isotype-matched control antibody. All sorting experiments were performed using FACSAria III (BD Bioscience) in the flow cytometer core of the Tel Aviv University. PIR-A/B expression was calculated by defining the delta mean fluorescent intensity between anti-PIR-A/B stain and isotype control. The expression of PIR-A was deduced by staining WT and *Pirb*^−/−^ cells with anti-PIR-A/B, which enables us to determine the relative expression of PIR-A (present on the surface of *Pirb*^−/−^ cells vs. PIR-A and PIR-B on the surface of WT cells as described previously^[@R19],\ [@R24]^.

Immunoprecipitation and phosphorylation assays {#S19}
----------------------------------------------

Siglec-F^+^Annexin-V^−^ cells were sorted from LDBM *Pirb*^−/−^ cell cultures and lysed in MPER lysis buffer (Pierce Endogen) supplemented with protease inhibitor cocktail (Sigma-Aldrich) on ice for 30 min. The cell lysate was pre-cleared and PIR-A immunoprecipitated using Protein A/G-conjugated anti-PIR-A/B antibodies or isotype-matched control (Dynabeads, Invitrogen). Custom-designed membranes coated with various antibodies were purchased from Hypromatrix. The immunoprecipitated PIR-A:protein complex was diluted in 2 ml of PBS and incubated with the pre-coated membrane. After washing, the membrane was incubated with anti-mouse phosphotyrosine conjugated to horseradish peroxidase (pY99; Santa Cruz Biotechnology)^[@R19]^. The membrane was developed using enhanced chemiluminescence (ECL)-plus (GE Healthcare).

Colony formation assays {#S20}
-----------------------

A total of 1 × 10^5^ bone marrow-nucleated cells in a volume of 0.1 ml was plated in 0.9 ml methylcellulose media (MethoCult 3234, Stem Cell Technologies), supplemented with 20 ng/ml mouse rIL-5 (50 ng/ml), rIL-3 (20 ng/ml) or rGM-CSF (10 ng/ml) (Peprotech), and placed in a humidified incubator with 5% CO~2~ at 37 °C. Colonies containing at least 50 cells were counted 10 days after incubation. The number of colonies/10^5^-nucleated bone marrow cells was calculated. Relative cell counts were determined using flow cytometry by obtaining a fixed amount of colonies and acquiring events for 120 s as described^[@R43]^.

Annexin-V apoptotic assay {#S21}
-------------------------

Apotosis was detected using an Annexin V apoptosis detection kit (eBioscience), according to the manufacturer's instructions.

ELISA {#S22}
-----

Bronchoalveolar lavage fluid CCL17, IL-4 and IL-13 were assessed using a commercial ELISA (R&D Systems Duo Set, Lower detection limits: 15.62, 3.91 and 62.5 pg/ml, respectively). Serum IgE was measured using a commercial kit purchased from BD bioscience according to the manufacturers' instructions. Lower detection limit for IgE was 15 pg/ml.

Bone marrow-derived macrophage and dendritic cell generation {#S23}
------------------------------------------------------------

Macrophages and dendritic cells were grown from the BM of WT and *Pirb*^−/−^ mice. Briefly, BM cells were harvested and cultured in the presence of M-CSF or GM-CSF (20 ng/ml, Peprotech), respectively, for 7-9 days.

Bone marrow chimera mice {#S24}
------------------------

Syngeneic BM chimeras were generated as described^[@R33],\ [@R48]^. Briefly, WT C57BL/6 mice were exposed to a single-lethal total body irradiation of 950 rad. One day after irradiation a 1:1 mixture of 5 × 10^6^ BM cells obtained from CD11c-DTR mice (CD45.1^+^) and WT or *Pirb*^−/−^ BM cells (CD45.2^+^) was injected into the irradiated mice, thus generating mixed BM chimeras. Thereafter, the mice were allowed to rest for 10 weeks and engraftment was validated in PB samples using anti-CD45.1 and anti-CD45.2 staining. Following confirmation of engraftment, the mice were challenged with Asp extract as described above. To deplete CD11c^+^ cells, diphtheria toxin (DTx) (8 ng/g body weight) was injected (intraperitoneally) every other day starting 24 h prior to the initial allergen challenge. CD11c^+^ cell depletion was monitored by flow cytometry using anti-CD45.1 and anti-CD11c staining.

Statistical analysis {#S25}
--------------------

Data were analyzed by ANOVA followed by Tukey post-hoc test using GraphPad Prism 4. Alternatively, several experiments were analyzed by Student's *t*-test. Data are presented as mean ± s.e.m., and values of *P* \< 0.05 were considered statistically significant.
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![*Pirb*^−/−^ low-density bone marrow-derived cells fail to differentiate into mature eosinophils in vitro\
Low-density bone marrow cells were obtained from wild-type (WT) and *Pirb*^−/−^ mice and differentiated in vitro into eosinophils. Representative photomicrograph images at the indicated time points of stained cytospins (a) and day 14 total cell counts (b) are shown. Filled and broken black arrows (a) indicate single nucleated and multi-nucleated myeloid cells, respectively. CCR3 surface expression (c), eosinophil major basic protein (*Mbp*, d), cell size and granularity (e), *Gata1* (f) and *Gata2* (g) expression were assessed in LDBM WT and *Pirb*^−/−^ cells. All qPCR analyses were normalized to the house keeping gene hypoxanthine-guanine phosphoribosyltransferase (*Hprt*). In (h), total eosinophil numbers as determined by CCR3^+^Siglec-F^+^ cells is depicted. Assessment of CD45^+^CD34^+^Lin^−^Sca-1^−^C-Kit^int^IL-5Rα^+^ eosinophil progenitors (EoPs) (i-j) and IL-5 receptor (R) α expression in EoPs (k) is shown. ns-non significant, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Data are representative of at least five independent experiments conducted in triplicates (a-e); mean and s.e.m. of cultures obtained from three (f-h) or five (j-k) mice per group.](nihms-527418-f0001){#F1}

![PIR-B regulates eosinophil apoptosis during low-density bone marrow-derived eosinophil differentiation\
Low-density bone marrow (LDBM) cells were obtained from wild-type (WT) and *Pirb*^−/−^ mice and differentiated in vitro. Representative photomicrograph images at the indicated time points of apoptotic eosinophils (a) as well as engulfed eosinophils (b) are shown. Representative density plot analysis (c) and a summary of annexin-V propidium idodide (PI) stained cells (d) is depicted. Numbers in each quadrant indicates the percentage of cells corresponding with this quadrant. Representative density plots of anti-Siglec F and annexin-V stained cells (e) and analysis of the percentage and total cell counts of Siglec-F^+^annexin V^+^ cells and Siglec-F^+^annexin V^−^ (f, g, h, i) is shown. LDBM cells were stained with anti-Siglec-F, annexin-V and anti-active caspase 3 (j), anti-Bim (l), or anti-GATA-1 (m) and expression was assessed using flow cytometry. Bim expression was assessed in cDNA obtained from LDBM cells by qPCR analysis (k) and normalized to the house keeping gene hypoxanthine-guanine phosphoribosyltransferase (*Hprt*). \**P* \< 0.05, \*\**P* \< 0.01,\*\*\**P* \< 0.001. Data are representative of at least five independent experiments conducted in triplicates (a-m); mean and s.e.m. of data obtained from three mice per group (d,f,g-I,k) or representative histograms from the respective experiments (j, i, m).](nihms-527418-f0002){#F2}

![PIR-B regulates IL-5- but not IL-3/GM-CSF-induced colony formation\
Low-density bone marrow cells were obtained from wild-type (WT) and *Pirb*^−/−^ mice and subjected to colony forming unit (CFU) assays in response to IL-5 (a, b, c), IL-3 (d, e) and GM-CSF (f, g). Total CFU counts (a, d, f) and relative cell counts per CFU (b, e, g) were assessed. In addition, IL-5-induced CFUs from WT and *Pirb*^−/−^ cultures were obtained and stained with anti-Siglec-F and annexin-V. Thereafter, Siglec-F^+^ cells were assessed for annexin-V expression (c); ns-non significant, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Data are mean and s.e.m. of three independent experiments of three mice per group (a-g).](nihms-527418-f0003){#F3}

![PIR-B regulates eosinophil apoptosis in-vivo even in the presence of increased IL-5\
Bone marrow cells were obtained from naïve wild-type (WT) and *Pirb*^−/−^ mice. Siglec-F^+^CCR3^int^ and Siglec-F^+^CCR3^hi^ cells (a) were gated (R1 and R2, respectively) and assessed for annexin-V expression (b, c). BM neutrophils and monocytes were gated (d) and assessed for annexin-V expression (d). PB was obtained from naïve WT and *Pirb*^−/−^ mice and assessed for circulating eosinophil levels using anti-Siglec-F and anti-CCR3 staining (e, f). WT and *Pirb*^−/−^ mice were treated with anti-IL-5 (TRFK5) or isotype control antibodies (Iso). Thereafter, bone marrow cells were stained with anti-Siglec-F and anti-CCR3 and the levels of Siglec-F^+^CCR3^int^ (g) and Siglec-F^+^CCR3^hi^ (h) cells as well as PB eosinophils (i) were assessed. In addition, the expression of PIRs was assessed on the surface of blood eosinophils (j). IL-5 was administered daily for 5 consecutive days and PB and BM were obtained. BM cells were stained with anti-Siglec-F, anti-CCR3 and bone marrow Annexin-VSiglec-F^+^CCR3^int^ and Annexin-VSiglec-F^+^CCR3^hi^ cells were gated (R1 and R2, respectively) and assessed for annexin-V expression (k, l). The levels of PB eosinophils were assessed (m). Expression of PIRs in BM (n, o) and PB (p) eosinophils is shown; ns-non significant, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Data are representative histograms, dot-plots and mean and s.e.m. of at least fifteen mice (a-f); or mean and s.e.m of two independent experiments with five to seven mice per group (g-p).](nihms-527418-f0004){#F4}

![Increased eosinophil development and decreased apoptosis in the absence of MHC-I expression\
Low-density bone marrow cells were obtained from wild-type (WT) and *B2m***^−/−^** mice and subjected to colony forming unit (CFU) assays in response to IL-5 (a-c). Thereafter, total CFU counts (a) and relative cell counts per CFU (b) were assessed. In addition, IL-5-induced CFUs from WT and *B2m***^−/−^** cell cultures were stained with anti-Siglec-F and annexin-V for assessment of apoptosis (c). Bone marrow cells were obtained from naïve WT and *B2m***^−/−^** mice. Cells were stained with anti-Siglec-F, anti-CCR3 and annexin-V. Thereafter, Siglec-F^+^CCR3^int^ and Siglec-F^+^CCR3^hi^ cells were gated and assessed for annexin-V expression (d, e); ns-non significant, \**P* \< 0.05. Data are mean and s.e.m of three independent experiments using three (a-c) and seven (d, e) mice.](nihms-527418-f0005){#F5}

![Neutralization of PIR-A in *Pirb*^−/−^ eosinophil cultures, attenuates eosinophil apoptosis\
The expression of PIR-A throughout the low-density bone marrow (LDBM)-derived eosinophil culture was determined at the indicated time points (a). In (b) Pearson correlation between PIR-A and Bim expression is shown (r=0.943, *P* = 0.0004). LDBM cells from wild type (WT) and *Pirb*^−/−^ mice were obtained and eosinophils were grown untreated (UT), in the presence of anti-PIR-A/B, or isotype control antibodies (Iso). Representative dot plots (c) and a summary of the flow cytometric analysis of anti-Siglec-F and annexin-V stained LDBM cells is shown (d, e). Cells were stained with modified Wright Giemsa stain and cellular morphology was assessed (f). Viable (i.e. Siglec-F^+^Annexin-V^−^) *Pirb*^−/−^ cells were sorted and PIR-A immunoprecipitated. Thereafter, antibody coated membranes were treated with anti-phospho-tyrosine antibodies conjugated to horseradish peroxidase and PIR-A:protein interactions were assessed (g). Representative flow cytometric histogram plot (h) and quantitative analysis of phopsho-Erk 1/2 expression in Siglec-F^+^Annexin-V^−^ and Siglec-F^+^Annexin-V^+^ cells from WT and *Pirb*^−/−^ cells is shown (i). Expression of PIR-A and PIR-B on the surface of eosinophils from various *in vivo* sources is depicted (j); \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Data are representative dot-plots and mean and s.e.m of five experiments conducted in duplicates (a-f); representative blots of one out of three independent experiments (g); representative histogram plot and pooled mean and s.e.m from five mice; and mean and s.e.m of at least five mice.](nihms-527418-f0006){#F6}

![*Pirb*^−/−^ mice display increased bone marrow eosinophil apoptosis as well as decreased PB and tissue eosinophilia following mucosal aeroallergen challenge\
Wild-type (WT) and *Pirb*^−/−^ mice were challenged with saline or *Aspergillus fumigatus* (Asp). Following six challenges, mice were bled and assessed for total serum IgE (a). Bone marrow was obtained and stained with anti-Siglec-F, anti-CCR3 antibodies and annexin-V. Siglec-F^+^CCR3^int^ and Siglec-F^+^CCR3^hi^ cells were gated and assessed for the frequencies of annexin-V positive cells (b, c). Saline- and Asp-challenged WT and *Pirb*^−/−^ mice were assessed for allergen-induced PB eosinophils (d), bronchoalveolar lavage fluid (BALF) eosinophil percentages (e) and total BAL eosinophils (f). Eosinophils from saline and Asp-challenged BALF were assessed for annexin-V positivity (g). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Data are representative of five experiments each containing six to eight mice per group (a-g).](nihms-527418-f0007){#F7}
